CU6

Clarity PharmaceuticalsASX:CU6 Stock Report

Market Cap

AU$275.3m

7D

-3.0%

1Y

n/a

Updated

14 Oct, 2021

Data

Company Financials +
CU6 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CU6 Overview

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.

Price History & Performance

Summary of all time highs, changes and price drops for Clarity Pharmaceuticals
Historical stock prices
Current Share PriceAU$1.12
52 Week HighAU$1.06
52 Week LowAU$1.71
Beta0
1 Month Change-16.42%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-25.33%

Recent News & Updates

Shareholder Returns

CU6AU PharmaceuticalsAU Market
7D-3.0%-0.5%0.3%
1Yn/a-3.6%17.9%

Return vs Industry: Insufficient data to determine how CU6 performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CU6 performed against the Australian Market.

Price Volatility

Is CU6's price volatile compared to industry and market?
CU6 volatility
CU6 Beta0
Industry Beta1.31
Market Beta1

Stable Share Price: CU6 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: Insufficient data to determine CU6's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aColin Bigginhttps://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.

Clarity Pharmaceuticals Fundamentals Summary

How do Clarity Pharmaceuticals's earnings and revenue compare to its market cap?
CU6 fundamental statistics
Market CapAU$275.34m
Earnings (TTM)-AU$10.22m
Revenue (TTM)AU$3.20m

89.8x

P/S Ratio

-28.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CU6 income statement (TTM)
RevenueAU$3.20m
Cost of RevenueAU$0
Gross ProfitAU$3.20m
ExpensesAU$13.42m
Earnings-AU$10.22m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.04
Gross Margin100.00%
Net Profit Margin-319.77%
Debt/Equity Ratio0.0%

How did CU6 perform over the long term?

See historical performance and comparison

Valuation

Is Clarity Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CU6 (A$1.12) is trading below our estimate of fair value (A$33.33)

Significantly Below Fair Value: CU6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CU6 is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: CU6 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CU6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CU6 is overvalued based on its PB Ratio (14.1x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is Clarity Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

72.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CU6 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: CU6 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CU6's is expected to become profitable in the next 3 years.

Revenue vs Market: CU6's revenue (50.4% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: CU6's revenue (50.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CU6's Return on Equity is forecast to be low in 3 years time (6%).


Past Performance

How has Clarity Pharmaceuticals performed over the past 5 years?

-47.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CU6 is currently unprofitable.

Growing Profit Margin: CU6 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CU6's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CU6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CU6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: CU6 has a negative Return on Equity (-50.41%), as it is currently unprofitable.


Financial Health

How is Clarity Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CU6's short term assets (A$22.5M) exceed its short term liabilities (A$2.3M).

Long Term Liabilities: CU6's short term assets (A$22.5M) exceed its long term liabilities (A$84.7K).


Debt to Equity History and Analysis

Debt Level: CU6 is debt free.

Reducing Debt: CU6 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CU6 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CU6 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 36.7% each year.


Dividend

What is Clarity Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CU6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CU6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CU6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CU6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CU6's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average board tenure


CEO

Colin Biggin

2yrs

Tenure

AU$907,434

Compensation

Dr. Colin David Biggin, Ph D., has been Managing Director, Chief Executive Officer and Executive Director at Clarity Pharmaceuticals Ltd since October 1, 2019. Dr. Biggin joined Clarity Pharmaceuticals Pty...


CEO Compensation Analysis

Compensation vs Market: Colin's total compensation ($USD668.46K) is about average for companies of similar size in the Australian market ($USD563.48K).

Compensation vs Earnings: Colin's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: CU6's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: CU6 only recently listed within the past 12 months.


Top Shareholders

Company Information

Clarity Pharmaceuticals Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Clarity Pharmaceuticals Ltd
  • Ticker: CU6
  • Exchange: ASX
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$275.342m
  • Shares outstanding: 256.13m
  • Website: https://www.claritypharmaceuticals.com

Location

  • Clarity Pharmaceuticals Ltd
  • National Innovation Centre
  • 4 Cornwallis Street
  • Sydney
  • New South Wales
  • 2015
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/14 07:02
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.